In-depth characterization of a cysteine-linked ADC disitamab vedotin by multiple LC-MS analysis methods and cutting-edge imaged capillary isoelectric focusing coupled with native mass spectrometry.

J Chromatogr A

National Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Daxing District, Beijing, 102629, China. Electronic address:

Published: November 2024

The characterization of cysteine-linked antibody‒drug conjugates (ADCs) can be more challenging than that of monoclonal antibodies (mAbs) and lysine-linked ADCs because the interchain disulfide bonds are reduced for payload conjugation, and the chains are noncovalently bonded to each other. Furthermore, payload conjugation and disulfide bond reduction/scrambling may introduce additional charge heterogeneity to biomolecules. This study illustrates an innovative workflow employing multiple separation techniques and tandem high-resolution mass spectrometry for comprehensive and in-depth characterization of disitamab vedotin, a recent-generation cysteine-linked ADC, including reversed-phase liquid chromatography (RPLC), ion exchange chromatography (IEX) and image capillary isoelectric focusing (icIEF). RPLC was employed for reduced chains analysis, subunit analysis and peptide mapping. IEX and icIEF were used for charge heterogeneity analysis. The innovation of the integrated methodology emphasizes the importance of cutting-edge icIEF-MS online coupling under near-native conditions to reveal the heterogeneity of disitamab vedotin.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chroma.2024.465353DOI Listing

Publication Analysis

Top Keywords

disitamab vedotin
12
in-depth characterization
8
characterization cysteine-linked
8
cysteine-linked adc
8
capillary isoelectric
8
isoelectric focusing
8
mass spectrometry
8
payload conjugation
8
charge heterogeneity
8
adc disitamab
4

Similar Publications

Objective: To explore the efficacy of c in the multiline treatment of late-stage lung adenocarcinoma with Her-2 overexpression and epidermal growth factor receptor (EGFR) mutations.

Methods: We summarize the diagnosis and treatment of a female patient with EGFR 21L858R mutation combined with Her-2 overexpression in advanced lung adenocarcinoma, and analyze the effect of c in her treatment process.

Results: The patient was diagnosed with lung adenocarcinoma 8 years ago.

View Article and Find Full Text PDF

Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase 1b/2 dose-escalation and dose-expansion study.

Ann Oncol

December 2024

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital, Beijing, China. Electronic address:

Background: HER2-targeted antibody-drug conjugates (ADCs) such as disitamab vedotin (DV) and trastuzumab deruxtecan (T-Dxd) have emerged as effective treatment options and received regulatory approvals for HER2 expressing locally advanced or metastatic urothelial carcinoma (la/mUC). In addition, ADCs in combination with immunotherapy have demonstrated anti-tumor activity. The current study aimed to evaluate the combination of DV and toripalimab in patients with la/mUC.

View Article and Find Full Text PDF
Article Synopsis
  • A study evaluated the effectiveness and safety of Disitamab Vedotin (RC48) for treating advanced HER2-positive and HER2-low metastatic breast cancer (MBC) among Chinese patients.
  • *A total of 154 patients were analyzed, revealing a median progression-free survival of 5.06 months and an objective response rate of 36.36%, with HER2-positive patients faring better than those with low HER2 expression.
  • *The results indicate that RC48 is a promising treatment with a good safety profile, and combining it with other therapies could enhance its effectiveness for these patients.
View Article and Find Full Text PDF
Article Synopsis
  • This study investigated the effectiveness of a new antibody-drug conjugate, Disitamab vedotin (RC48), in treating advanced non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 alterations, with considerable focus on real-world clinical outcomes.
  • The results showed that 95.5% of patients received RC48 in combination therapy, achieving an overall objective response rate (ORR) of 45.5% and a disease control rate (DCR) of 90.9%, with a median progression-free survival (PFS) of 7.5 months.
  • Key findings indicated that combination therapies, especially with platinum or TKI, resulted in higher response rates, while most
View Article and Find Full Text PDF

Background: Disitamab vedotin (RC48-ADC), an antibody-drug conjugate (ADC), combines specific antibody disitamab with cytotoxicity monomethyl auristatin E to effectively target the human epidermal growth factor receptor 2 (HER2) protein on tumor cells for precise elimination. Recent studies have demonstrated that RC48-ADC offers therapeutic benefits for patients with HER2-positive and HER2-low-expression breast cancer (BC). However, a thorough exploration of its efficacy and safety in real-world settings for patients with metastatic breast cancer (mBC) is currently lacking.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!